Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editor's pick

21-08-2019 | Tofacitinib | Feature | Article

Tofacitinib black box warning: A cause for concern?

Roy Fleischmann puts the new FDA boxed warning of increased pulmonary embolism and death risk with tofacitinib into context for rheumatologists and their patients.

14-08-2019 | Rheumatoid arthritis | Highlight | News

Support for switching between upadacitinib and adalimumab in RA patients

48-week results from the SELECT-COMPARE study indicate that upadacitinib has sustained efficacy in patients with rheumatoid arthritis, and that individuals with an inadequate response to upadacitinib or adalimumab may benefit from switching to the alternate therapy.

13-08-2019 | Systemic lupus erythematosus | Editorial | Article

Neuropsychiatric systemic lupus erythematosus: Issues in diagnosis and management

Antigone Pieta, Dionysis Nikolopoulos, and Antonis Fanouriakis discuss the causes and management of neuropsychiatric systemic lupus erythematosus, and outline unmet needs in the diagnosis and treatment of this disease.

Latest from across the site

22-08-2019 | Rheumatoid arthritis | News

Neutrophil biomarkers show promise for predicting RA prognosis

Neutrophil-derived biomarkers correlate with disease activity and can predict joint space narrowing and erosive disease among patients with rheumatoid arthritis, researchers report.

21-08-2019 | Rheumatoid arthritis | News

Upadacitinib gains FDA approval for RA

Click through for more information on this approval

21-08-2019 | Vaccination | News

EULAR updates vaccination guidance for patients with rheumatic diseases

EULAR has developed up-to-date guidelines for the use of vaccinations in patients with rheumatic diseases, based on a systematic literature review and expert opinion.

21-08-2019 | Tofacitinib | Feature | Article

Tofacitinib black box warning: A cause for concern?

Roy Fleischmann puts the new FDA boxed warning of increased pulmonary embolism and death risk with tofacitinib into context for rheumatologists and their patients.

19-08-2019 | Rheumatoid arthritis | News

Serious infection risk in TNF inhibitor-treated RA patients characterized

One study has demonstrated an elevated risk for serious infection among rheumatoid arthritis patients treated with tumor necrosis factor inhibitors versus conventional Disease‐Modifying Antirheumatic Drugs, whereas another has found no increased risk.

16-08-2019 | Rheumatoid arthritis | News

Frailty linked to worsening function in RA patients

Frailty may be a risk factor for worsening physical function among people with rheumatoid arthritis, research suggests.

Latest from us on Twitter

Trending this week

Meet our Editorial Board

New Content Item Meet our Advisory Board

Image Credits